In adults hospitalized with COVID-19, more than half showed abnormal thyroid hormone levels at admission, and those with these abnormalities were significantly more likely to have severe illness. This finding is from the abstract summary - full study details were not available.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of multiple cohort studies could determine whether thyroid dysfunction at COVID-19 admission consistently predicts severity across diverse populations and settings.
A systematic review and meta-analysis of all prospective cohort studies reporting thyroid function tests and disease severity in hospitalized COVID-19 patients, including at least 10,000 participants across multiple countries, adjusting for age, sex, comorbidities, and inflammatory markers, with predefined criteria for defining severe disease and thyroid dysfunction.
An RCT could test whether modulating thyroid hormone levels during acute infection alters disease severity, establishing a potential causal role.
A double-blind, placebo-controlled trial of 500 hospitalized COVID-19 patients with confirmed NTIS, randomized to receive low-dose liothyronine (T3) vs. placebo for 7 days, with primary outcome being change in SOFA score and duration of oxygen support.
A prospective cohort study could confirm whether the association between admission thyroid dysfunction and disease severity holds after controlling for key confounders.
A multicenter prospective cohort of 1,000 hospitalized adults with confirmed COVID-19, measuring TSH, fT3, fT4, anti-TPO, and inflammatory markers at admission and daily for 7 days, with severity defined by WHO ordinal scale, adjusting for age, BMI, diabetes, and CRP levels.
A case-control study could compare thyroid profiles of severely ill vs. mildly ill COVID-19 patients to identify patterns predictive of severity.
A matched case-control study comparing 300 severely ill (ICU-admitted) and 300 mildly ill (ward-treated) COVID-19 patients, matched for age, sex, and comorbidities, measuring pre-infection and admission TFTs and autoantibodies to identify predictive thresholds.
A cross-sectional study could describe the prevalence of thyroid dysfunction in a single snapshot of hospitalized patients, but cannot assess progression or causality.
A single-timepoint survey of 500 hospitalized COVID-19 patients measuring TFTs and autoantibodies at admission, with severity classified by oxygen requirement, to estimate prevalence and crude association.